Yale Bulletin and Calendar

March 30, 2007|Volume 35, Number 23

Antidepressants increase protein in brain that leads to new cell growth, researchers discover

Antidepressants increase the presence of a growth factor in the brain, which then leads to a proliferation of new cells, according to a study by Yale School of Medicine researchers in this week's Proceedings of the National Academy of Sciences.

The study describes for the first time the molecular mechanisms and the identity of the protein, vascular endothelial growth factor (VEGF), which underlie the actions of antidepressants on new cell growth and behavior.

"One in five Americans have depression, yet the neural mechanisms underlying depression and the actions of antidepressants remain unknown," says Ronald Duman, senior author and professor of psychiatry at Yale. "These findings provide important, fundamental and new information on the actions of these highly prescribed drugs. The data also has implications for understanding many stress-related disorders."

Duman and Jennifer Warner-Schmidt, a former graduate student at Yale now at the Rockefeller Institute, found in a rodent study that VEGF levels are increased by chronic administration of either of two major classes of antidepressant medications. Conversely, blocking the effects of VEGF prevents new cell birth in response to the medications.

Duman says recent studies demonstrated that stress decreases the expression of VEGF in the hippocampus, a region of the brain involved in the control of emotion, mood, learning and memory, and this could contribute to the atrophy and loss of cells caused by stress and depression.

In prior groundbreaking research Duman found that antidepressants increase the expression of growth factors in the hippocampus and other regions of the brain. He also found that antidepressants increase the birth of new neurons in the hippocampus.

According to Duman, future studies could look at VEGF and related pathways for genetic mutations that might contribute to depression, or make a person more susceptible to depression. VEGF signaling also could provide targets for the development of novel, faster acting and more effective therapeutic agents.

-- By Jacqueline Weaver

T H I SW E E K ' SS T O R I E S

Concern about environment is on the rise, according to Yale poll

Website offers info on Yale's environmental, sustainability efforts

Centennial celebration to honor Paul Mellon

In her novel, student tells human story of Biafran War

Elizabeth Alexander wins inaugural Jackson Poetry Prize

New associate provost named: Cynthia Smith

Photographic archive offers multi-faceted portrait of America

'Lulu' at Yale Rep is tale of obsession, sexuality and violence

Study finds brain's 'default mode' is abnormal in schizophrenic patients

Antidepressants increase protein in brain that leads to . . .

Study shows financial barriers contribute to less follow-up care . . .

Exhibit reveals corruption behind the 'glitter' of East India Company

Inaugural symposium to explore transnational history of sexuality

Events to help prepare citizens for a public health emergency

The game of kings (and queens and bishops)

Campus Notes